Plain-English translation of NCT06925217 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 2 Diabetes research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a fully closed-loop insulin delivery system called the CamAPS HX, which uses an insulin pump, glucose sensor, and smartphone app that work together to automatically adjust your insulin doses throughout the day. The study is designed for people with type 2 diabetes who also have chronic kidney disease. Researchers want to see whether this smart system can better protect your kidneys compared to standard insulin therapy with a regular glucose monitor.
People with both type 2 diabetes and kidney disease often struggle to manage their blood sugar well, and high blood sugar can damage the kidneys further. This trial is exploring whether the medication can help by keeping blood sugar more stable and steady, which might slow down kidney damage.
You likely qualify if…
You likely don't qualify if…
If you join, you'll have about 6 visits over 6 months, plus phone check-ins at weeks 1, 4, 8, 12, and 20. At your first visit, you'll wear a hidden glucose sensor for 2 weeks so the research team can see how your blood sugar normally behaves. Then you'll be randomly assigned to either use the smart insulin pump system or continue with standard insulin therapy plus a regular glucose monitor. Both groups will wear a glucose sensor. You'll have training on your assigned device, and the research team will follow up with you regularly to make sure everything is working well and to adjust settings as needed.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
Switzerland